Hansa Biopharma AB
(OSTO:HNSA)
kr
40.5
3 (8%)
Market Cap: 2.66 Bil
Enterprise Value: 3.06 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 77/100 Hansa Biopharma AB Redeye Interview Transcript
Oct 22, 2021 / NTS GMT
Release Date Price:
kr105.3
(-3.48%)
Johan Unnerus
Redeye AB, Research Division - Senior Equity Analyst
My name is Johan Unnerus. I'm an analyst at the life science team at Redeye.
Today, we have the pleasure to feature Hansa Biopharma with the CEO, Søren Tulstrup. And we have some questions for Søren.
SÃ;ren Tulstrup;publ;President;CEO
Hansa Biopharma AB
¸ - ()-&
Thank you. Good to be here.
Johan Unnerus
Redeye AB, Research Division - Senior Equity Analyst
Excellent, yes.
Questions & Answers
Johan Unnerus;SÃ;ren Tulstrup;publ
Redeye AB, Research Division - Senior Equity Analyst;Hansa Biopharma AB
You just reported your Q3, and overall, congratulations. You -- Idefirix is approved. And it's addressing a need for patients that hasn't had any products on the market that are highly sensitized ahead of kidney transplants. It's a big step forward, isn't it?
¸ - ()
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot